comparemela.com

Latest Breaking News On - Retinal cell - Page 1 : comparemela.com

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion Maintenance or increases.

Israel generalUnited statesDavid telanderBrianm culleyRoche groupFoundation fighting blindnessExchange commissionOregon health science university casey eye instituteRetinal consultants medical groupEterna therapeutics incLineage cell therapeutics incLineage cell therapeuticsGene therapy innovationOregon healthScience university casey eyeRetinal pigment epithelium

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

MALVERN, Pa., April 29, 2024 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that.

United statesUniversity of arizonaBenjamin bakallOcugen incExchange commissionClinical research at associated retina consultantsHead of communicationsOregon healthNuclear hormone receptorCollege of medicineScience university casey eye instituteFoundation fighting blindnessClinical researchAssociated retina consultantsClinical assistant professorRetinal cell

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in.

United statesDavid telanderLineage cell therapeutics incCasey eye instituteRetinal consultants medical groupExchange commissionEterna therapeutics incOregon health science university casey eye instituteRoche groupFoundation fighting blindnessLineage cell therapeuticsGene therapy innovationHyatt regency seattleOregon healthScience university casey eyeRetinal pigment epithelium

A Promising New Approach For Glaucoma

Recent medical breakthroughs in RGC (retinal ganglion cell) replacement therapy offer hope for those suffering from glaucoma.

Retinal ganglionGanglion cellsRetinal cellMaking retinal ganglion cellsTreatment for glaucomaGlaucoma treatmentsRetinal cell therapyRetinal ganglion cellsRetinal cell replacementsCell therapyCell therapy for glaucoma

Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting

/PRNewswire/ Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today that Chief Medical Officer.

United statesJay barthShimyn slomovicRomesh subramanianOrleans ernestn morial convention centerFoundation fighting blindnessOregon health science universityCasey eye instituteAssociation for researchChief medical officer jay barthEighth annual retinal cellGene therapy innovation summitMolecular biology shimyn slomovicRetinal cellChief executive officerOregon health

vimarsana © 2020. All Rights Reserved.